Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TARA
Strong SellSinkerProtara Therapeutics, Inc. · Healthcare · United States · $226M · Avg Vol: $1M/d
9
StockRankGet insider-trade alerts
Q
32
V
32
M
18
P/E (TTM)
—
ROE
-45.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 1.0M | — |
| EPS | -1.17 | -0.72 | -2.17 | -1.34 | — | -1.36 | -1.39 | -1.69 | — |
| Shares | 56.2M | 56.2M | 35.0M | 53.6M | -4.7% | 59.1M | — | — | — |
| Debt | 6.4M | 5.5M | 4.5M | 3.4M | -19.3% | 2.7M | — | — | — |
| Equity | 102.1M | 68.3M | 167.1M | 196.4M | 24.4% | — | — | — | — |
| Op CF | -26.5M | -37.6M | -35.8M | -56.4M | — | -66.1M | — | — | — |
| Inv CF | 14.9M | 53.1M | 19.2M | -139.5M | — | — | — | — | — |
| Fin CF | -90.0K | -91.0K | 139.9M | 82.7M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-6.0%
SMA 50SMA 200
Close
$3.79
RSI (14)
43.2
52W High
$7.82
From 52W High
0.5%
SCORE BREAKDOWN
Quality
32
ROIC
-35.3%21.5
ROE
-45.8%19.8
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-27.0%15.8
Piotroski
29.5
Int. Cover
—N/A
D/E Ratio
0.02x81.2
Current Ratio
10.97x88.7
Value
32
P/E (TTM)
—N/A
EV/EBITDA
-1.2x25.0
P/FCF
—N/A
P/B
1.4x74.4
P/S
—N/A
Div Yield
—N/A
Momentum
18
52W High %
48%22.0
RS 6M
-45%16.0
SMA 50/200
0.79x14.5
EPS Rev 4W
-2.9%17.7
EPS Rev 12W
—N/A
EPS Improve
-24%14.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$226M
P/E (Forward)
-2.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TARA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TARA | Protara Therapeutics, Inc.(you) | $226M | 9 | Strong Sell |
| NBP | NovaBridge Biosciences | $213M | 10 | Strong Sell |
| RNA | Atrium Therapeutics, Inc. | $233M | 11 | Strong Sell |
| NERV | Minerva Neurosciences, Inc. | $231M | 12 | Strong Sell |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $211M | 7 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 10 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%